Cognition Effects of Low-Grade Hypoxia.

INTRODUCTION: The effects of low-grade hypoxia on cognitive function are reported in this paper. The study compared cognitive function during short exposures at four different altitudes. METHODS: Ninety-one subjects were exposed to simulated altitudes of ground level, 1524, 2438, and 3658 m (5000, 8000, and 12,000 ft) in the Brooks City-Base altitude pressure chamber in a balanced design. Oxygen saturation, heart rate, and cognitive performance on seven different cognitive tasks were measured. In addition, subjects indicated their symptoms from a 33-item subjective symptom survey. RESULTS: As designed, oxygen saturation decreased and heart rate increased with higher altitudes. Very small degradations in performance were found at the two highest altitudes for only two of the cognitive tasks (continuous performance and grammatical reasoning). In the subjective symptom survey, 18 of the 33 possible symptoms were more common at 3658 m (12,000 ft) than at ground level. CONCLUSIONS: The findings indicated a minimal influence of low-grade hypoxia on cognitive performance in contrast to some existing classic symptoms of hypoxia. Pilmanis AA, Balldin UI, Fischer JR. Cognition effects of low-grade hypoxia. Aerosp Med Hum Perform. 2016; 87(7):596-603.

G Protection When Adding Pressurized Sleeves and Gloves to a Representative G-Suit Ensemble.

BACKGROUND: In a previous study, pressurized sleeves and gloves were found to substantially diminish or eliminate G-induced arm pain. Since this equipment presumably acts similarly to a G suit for the arms and hands, it was hypothesized that higher inflation pressures might provide an additional increment of G protection. METHODS: In a human-rated centrifuge, 15 well trained subjects using Combat Edge and ATAGS G-protective equipment were exposed to gradual and rapid onset relaxed G exposures as well as rapid onset straining and simulated aerial combat maneuver G exposures up to + 9 Gz with and without pressurized sleeves and gloves. RESULTS: The pressurized sleeves and gloves did not show any improvement in G tolerance or endurance compared to the control. However, significantly lower heart rates (6-12%) and subjective effort (11%), along with slightly less peripheral vision loss, suggest a decreased work load when wearing the pressurized sleeves and gloves. A trend to shorter time on target in a tracking task was found with the pressurized sleeves and gloves, likely due to decreased mobility of the hands, thus affecting control stick input. CONCLUSIONS: G tolerance and endurance were not improved by the pressurized sleeves and gloves. However, a lower heart rate and a decreased subjective effort level and peripheral vision loss indicated that the subjects did not have to work as hard with this equipment.

Inferior g protection with an electrical muscle stimulation suit compared to a standard g-suit.

BACKGROUND: At +1 Gz, electrical muscle stimulation (EMS) has been shown to increase systemic blood pressure similarly to a standard G-suit or lower body muscle straining. It was hypothesized that EMS might improve G protection at increased G levels. METHODS: An EMS suit was developed with electrodes over the calves, thighs, gluteal, and abdominal muscles. Using nine subjects, the EMS suit was compared to a standard five-bladder G-suit during various G profiles up to +9 Gz in a human-rated centrifuge with EMS activated by electrical muscle stimulators at G levels at or above +4 Gz. The optimal EMS stimulation for a solid muscle contraction was determined for each muscle group in each subject prior to the G exposures. RESULTS: The mean maximal G level attained in the standard suit was 1.1 G higher during a relaxed gradual onset profile, 1.5 G higher during a relaxed rapid onset profile, and 2.0 G higher during a straining rapid onset profile when compared to the EMS suit. During a simulated aerial combat maneuver (SACM) ride, duration was 46 s longer with the standard suit compared to the EMS. During the SACM, the average heart rate was 23 bpm lower with the standard suit compared to EMS. All of the above differences were statistically significant. Finally, there were four G-LOCs with the EMS and none with the standard suit. CONCLUSION: The tested EMS suit did not give sufficient G protection at high Gs for pilots, nor substitute for a standard G-suit, as indicated by lower G protection and the episodes of G-LOC.

Acceleration endurance with pressure breathing during G with and without a counterpressure vest.

INTRODUCTION: The purpose of this study was to test whether pressure breathing during G (PBC) without a counterpressure vest negatively influences G endurance or increases breathing fatigue during extended duration high-G exposures. METHODS: While using PBG, 10 subjects underwent 2 trials of +3 Gz exposures: once when wearing a counterpressure vest and once without. The exposures consisted of a relaxed, gradual G onset run until peripheral or central light loss, a straining rapid onset GC run to +6 Gz for 15 s, and a simulated aerial combat maneuver (SACM) G profile consisting of 10-s periods varying between +5 Gz and +9 Gz, during which subjects executed a hand-eye tracking task. The SACM endpoint was light loss or exhaustion. Subjects provided ratings of subjective effort and discomfort after the SACM. RESULTS: Significant differences were found between the vest and no-vest conditions for only 3 of 19 measures: heart rate under G and two measures of tracking ability. The vast majority of data indicated no difference between the vest and no-vest conditions for performance under G. DISCUSSION: This experiment supports previous studies and expands those previous results by increasing the duration of PBG exposure shown to not be influenced by wearing of the vest. We conclude that there is likely no practical advantage to wearing a counterpressure vest during PBG.

Air break during preoxygenation and risk of altitude decompression sickness.

INTRODUCTION: To reduce the risk of decompression sickness (DCS), current USAF U-2 operations require a 1-h preoxygenation (PreOx). An interruption of oxygen breathing with air breathing currently requires significant extension of the PreOx time. The purpose of this study was to evaluate the relationship between air breaks during PreOx and subsequent DCS and venous gas emboli (VGE) incidence, and to determine safe air break limits for operational activities. METHODS: Volunteers performed 30 min of PreOx, followed by either a 10-min, 20-min, or 60-min air break, then completed another 30 min of PreOx, and began a 4-h altitude chamber exposure to 9144 m (30,000 ft). Subjects were monitored for VGE using echocardiography. Altitude exposure was terminated if DCS symptoms developed. Control data (uninterrupted 60-min PreOx) to compare against air break data were taken from the AFRL DCS database. RESULTS: At 1 h of altitude exposure, DCS rates were significantly higher in all three break in prebreathe (BiP) profiles compared to control (40%, 45%, and 47% vs. 24%). At 2 h, the 20-min and 60-min BiP DCS rates remained higher than control (70% and 69% vs. 52%), but no differences were found at 4 h. No differences in VGE rates were found between the BiP profiles and control. DISCUSSION: Increased DCS risk in the BiP profiles is likely due to tissue renitrogenation during air breaks not totally compensated for by the remaining PreOx following the air breaks. Air breaks of 10 min or more occurring in the middle of 1 h of PreOx may significantly increase DCS risk during the first 2 h of exposure to 9144 m when compared to uninterrupted PreOx exposures.

Acceleration tolerance after ingestion of a commercial energy drink.

BACKGROUND: Caffeine ingestion has been demonstrated to increase physical performance in some situations. This study examined the ability of a commercial energy drink containing caffeine to enhance acceleration tolerance and strength under G load. METHODS: Eight experienced centrifuge subjects completed three separate experimental acceleration exposures following ingestion of 11.5 ml x kg(-1) bodyweight of (1) a commercial energy drink, providing 5.0 mg caffeine/kg bodyweight; (2) a commercial energy drink without caffeine; or 3) a placebo. The acceleration exposures consisted of a relaxed gradual onset run to peripheral light loss, a rapid onset run to 6 G for 15 s, and a simulated air combat maneuver (SACM) run of repeated alternations between 4.5 G for 15 s and 7 G for 15 s until volitional exhaustion. RESULTS: Relaxed G tolerance was 13% higher under the caffeinated energy drink session, whereas SACM duration did not differ among the drink conditions. Hip adductor muscle strength was 37% lower during the placebo session than during the other two sessions. CONCLUSION: Consumption of a caffeine-based energy drink may enhance relaxed G tolerance and may increase strength, but does not impact acceleration tolerance duration.

An electrical muscle stimulation suit for increasing blood pressure.

BACKGROUND: Electrical muscle stimulation (EMS) is used to strengthen muscles in rehabilitation of patients and for training of athletes. Voluntary muscle straining and an inflated anti-G suit increase the arterial blood pressure (BP) and give a pilot G protection during increased +Gz. This study's aim was to measure whether BP also increases with EMS of lower body muscles. METHODS: A suit with new cloth electrodes sewn into the garment was developed. There were 12 subjects who were tested in sitting position during 3 conditions with 10 consecutive periods of EMS, inflated anti-G suit (GS), or lower body muscle anti-G straining maneuvers (AGSM). BP was continuously measured noninvasively. RESULTS: The means of the baseline systolic BP, before each of the test conditions, were 127 +/- 16, 128 +/- 1, and 145 +/- 14 mmHg for GS, AGSM, and EMS, respectively. During inflation of the GS, execution of the AGSM, and EMS, mean systolic BP during the first 10 s was 143 +/- 15, 146 +/- 13, and 150 +/- 13 mmHg, respectively, with no statistical difference between the conditions. The corresponding mean resting heart rate before each test was 57-63 bpm for all conditions. During the test periods with GS, AGSM, and EMS, heart rate was 59 +/- 11, 79 +/- 16, and 61 +/- 15 bpm, respectively, with statistical differences (P < 0.001) between AGSM and the other two conditions. CONCLUSION: EMS created similar BP as GS and AGSM at 1 G and also had higher pre- and post-control values. Further studies are required to evaluate if this principle may be used for G protection of pilots.

Decompression sickness during simulated extravehicular activity: ambulation vs. non-ambulation.

BACKGROUND: Extravehicular activity (EVA) is required from the International Space Station on a regular basis. Because of the weightless environment during EVA, physical activity is performed using mostly upper-body movements since the lower body is anchored for stability. The adynamic model (restricted lower-body activity; non-ambulation) was designed to simulate this environment during earthbound studies of decompression sickness (DCS) risk. DCS symptoms during ambulatory (walking) and non-ambulatory high altitude exposure activity were compared. The objective was to determine if symptom incidences during ambulatory and non-ambulatory exposures are comparable and provide analogous estimates of risk under otherwise identical conditions. METHODS: A retrospective analysis was accomplished on DCS symptoms from 2010 ambulatory and 330 non-ambulatory exposures. RESULTS: There was no significant difference between the overall incidence of DCS or joint-pain DCS in the ambulatory (49% and 40%) vs. the non-ambulatory exposures (53% and 36%; p > 0.1). DCS involving joint pain only in the lower body was higher during ambulatory exposures (28%) than non-ambulatory exposures (18%; p < 0.01). Non-ambulatory exposures terminated more frequently with non-joint-pain DCS (17%) or upper-body-only joint pain (18%) as compared with ambulatory exposures, 9% and 11% (p < 0.01), respectively. DISCUSSION: These findings show that lower-body, weight-bearing activity shifts the incidence of joint-pain DCS from the upper body to the lower body without altering the total incidence of DCS or joint-pain DCS. CONCLUSIONS: Use of data from previous and future subject exposures involving ambulatory activity while decompressed appears to be a valid analogue of non-ambulatory activity in determining DCS risk during simulated EVA studies.

Partial pressure of nitrogen in breathing mixtures and risk of altitude decompression sickness.

BACKGROUND: Many aircraft oxygen systems do not deliver 100% O2. Inert gases can be present at various levels. The purpose of this study was to determine the effect of these inert gas levels on decompression sickness (DCS). METHODS: Subjects were exposed for 4 h to 5486 m (18,000 ft) with zero prebreathe, using either mild (Test A) or strenuous exercise (Test B), and breathing 60%N2/40%O2. Test C used a breathing mixture of 40%N2/60%O2 at 6858 m (22,500 ft) with zero prebreathe and mild exercise. Test D investigated a breathing mixture of 2.8%N2/4.2%argon/93%O2 with 4 h exposures to 7620 m (25,000 ft), mild exercise, and 90 min of preoxygenation. The controls were from previous studies using similar conditions and 100% O2. RESULTS: The DCS risk for Tests A and B and the Control for B was 7%; the Control for Test A was 0% (n.s.). Breathing the 40%N2/60%O2 mixture (Test C) resulted in 43% DCS compared with 53% DCS with 100% O2 (n.s.). When the 2.8%N2/4.2%argon/93%O2 mixture was used, the results showed 25% DCS compared with 31% DCS with 100% O2 (n.s.). CONCLUSIONS: The increased nitrogen and argon levels in the breathing gas while at altitudes of 5486 m to 7620 m did not increase DCS risk. These results support the concept of using the partial pressure gradient of inert gases instead of the percentage of N2 or argon in a breathing gas mixture to determine the risk of DCS during altitude exposure.

Altitude decompression sickness susceptibility: influence of anthropometric and physiologic variables.

INTRODUCTION: There is considerable variability in individual susceptibility to altitude decompression sickness (DCS). The Air Force Research Laboratory Altitude DCS Research Database consists of extensive information on 2980 altitude exposures conducted with consistent procedures and endpoint criteria. We used this database to quantify the variation in susceptibility and determine if anthropometric and/or physiologic variables could be used to predict DCS risk. METHODS: There were 240 subjects who participated in at least 4 of 70 exposure profiles in which between 5 and 95% of all subjects tested developed DCS symptoms. A subject/study ratio (SSR) was calculated by dividing the DCS experienced by a subject during all their exposures by the DCS incidence for all subjects who participated in the identical exposures. The SSR was used to identify the relative susceptibility of subjects for use in analyzing possible relationships between DCS susceptibility and the variables of height, weight, body mass index, age, percent body fat, and aerobic capacity. RESULTS: The DCS incidence was 46.5% during 1879 subject-exposures by subjects exposed at least 4 times. A significant relationship existed between higher DCS susceptibility and the combination of lower aerobic capacity and greater weight (p < 0.05). DISCUSSION: Despite a correlation, less than 13% of the variation in DCS susceptibility was accounted for by the best combination of variables, weight and VO2max. CONCLUSION: Differences in DCS susceptibility cover a wide range and appear to be related to some anthropometric and physiologic variables. However, there was insufficient correlation to allow prediction of an individual's susceptibility.

Pressure breathing without a counter-pressure vest does not impair acceleration tolerance up to 9 G.

INTRODUCTION: This study was to determine whether safe and adequate G-protection by pressure breathing during G (PBG) could be maintained if the COMBAT EDGE counter-pressure vest were eliminated to ensure aircrew do not unnecessarily endure a possible in-flight discomfort or distraction. METHODS: Centrifuge exposures up to +9 Gz were completed by 11 subjects, including 5 F-15 aircrew, using PBG at 60 mmHg pressure with and without the counter-pressure vest. Additional G-exposures using pressures of 0, 30, and 45 mmHg were performed without the vest. RESULTS: Elimination of the COMBAT EDGE counter-pressure vest did not significantly reduce G-tolerance. During gradual onset G exposure, the mean G level reached with PBG was 8.4 G without the vest and 8.2 G with the vest. In comparison, 6.7 G was reached without PBG. Mean times at G with rapid onset G exposure were 59 and 60 s, respectively, compared with 49 s without PBG. PBG, with or without the vest, was preferred by all test subjects. PBG at 60 mmHg produced the highest G protection and was preferred by the test subjects over lesser pressures. Subjects reported no adverse effects from the use of PBG without chest counter-pressure. CONCLUSION: The use of PBG and the anti-G straining manuever (AGSM) together enhances G tolerance and comfort more than AGSM alone. Elimination of the counter-pressure vest during use of PBG does not hinder an individual's ability to reach +9 Gz or complete a short duration simulated aerial combat maneuver G exposure. Further research is needed to determine if use of PBG without chest counter-pressure increases fatigue during multiple sorties or produces other aeromedical problems in operational environments.

Central nervous system decompression sickness and venous gas emboli in hypobaric conditions.

INTRODUCTION: Altitude decompression sickness (DCS) that involves the central nervous system (CNS) is a rare but potentially serious condition. Identification of early symptoms and signs of this condition might improve treatment. METHODS: We studied data from 26 protocols carried out in our laboratory over the period 1983-2003; all were designed to provoke DCS in a substantial proportion of subjects. The data set included 2843 cases. We classified subject-exposures that resulted in DCS as: 1) neurological DCS of peripheral and/or central origin (NEURO); 2) a subset of those that involved only the CNS (CNS); and 3) all other cases, i.e., DCS cases that did not have a neurological component (OTHER). For each case, echo imaging data were used to document whether venous gas emboli (VGE) were present, and their level was classified as: 1) any level, i.e., Grade 1 or higher (VGE-1); and 2) high level, Grade 4 (VGE-4). RESULTS: There were 1108 cases of altitude DCS in the database; 218 were classified as NEURO and 49 of those as CNS. VGE-1 were recorded in 83.8% of OTHER compared with 58.7% of NEURO and 55.1% of CNS (both p < 0.001 compared with OTHER). The corresponding values for VGE-4 were 48.8%, 37.0%, and 34.7% (p < 0.001, compared to OTHER). Hyperbaric oxygen (HBO) was used to treat about half of the CNS cases, while all other cases were treated with 2 h breathing 100% oxygen at ground level. DISCUSSION: Since only about half of the rare cases of hypobaric CNS DCS cases were accompanied by any level of VGE, echo imaging for bubbles may have limited application for use as a predictor of such cases.

Altitude decompression sickness at 7620 m following prebreathe enhanced with exercise periods.

INTRODUCTION: Over 80% altitude decompression sickness (DCS) was reported during a 4-h exposure with mild exercise to 7620 m (25,000 ft) without prebreathe. Prebreathe for more than 1 h would be necessary to reduce the DCS risk below 40%. Use of a single period of exercise to enhance prebreathe effectiveness has been successfully tested and used during some U-2 operations. The current tests used multiple exercise sessions to enhance prebreathe (MEEP) as a means of improving denitrogenation efficiency. METHODS: Two MEEP profiles, 30 or 60 min, preceded 4-h exposures to 7620 m with mild, upper-body exercise while breathing 100% oxygen. Resting prebreathe controls were from published studies at the same laboratory. Both MEEP profiles involved 10 min of strenuous dual-cycle ergometry (75% of maximal oxygen uptake) at the beginning of prebreathe. After a 15-min rest period during the 60-min prebreathe, an additional 5 min of strenuous ergometry was performed. Mild exercise was performed during 15 of the last 20 min of both prebreathe profiles. RESULTS: The 60-min MEEP resulted in 25% DCS and the 30-min MEEP 40% DCS (N.S.). The 25% incidence of DCS following the 60-min MEEP profile was significantly less than the 63% DCS following an equal-time, resting prebreathe control. Following the 30-min MEEP, DCS incidence was not greater than the incidence following a 60-min, resting prebreathe control. There was a lower incidence of venous gas emboli during the MEEP exposures than during resting control exposures. CONCLUSION: Denitrogenation with multiple periods of exercise provides a shorter alternative to resting prebreathe for reducing DCS risk during exposure to 7620 m.

Staged decompression to 3.5 psi using argon-oxygen and 100% oxygen breathing mixtures.

INTRODUCTION: The current extravehicular activity (EVA) space suit at 4.3 psia causes hand and arm fatigue and is too heavy for Martian EVA. A 3.5 psia EVA pressure suit requires increased preoxygenation time but would reduce structural complexity, leak rate, and weight while increasing mobility, comfort, and maintainability. On Mars, nitrogen and argon are available to provide the inert gas necessary for a fire-resistant habitat atmosphere, eliminating need for transport. This study investigated breathing argon/oxygen and 100% oxygen gas mixtures during staged decompression prior to exposure to 3.5 psia. METHOD: During this study, 40 subjects each completed 3 hypobaric exposures to 3.5 psia for 3 h in a reclined position: (A) a 4-h 25-min 14.7-psia (ground level) denitrogenation (100% oxygen breathing) prior to exposure to 3.5 psia; (B) the same as A, utilizing a 7.3-psia stage denitrogenation; and (C) the same as B, with 62% argon-38% oxygen (ARGOX) during the stage. Venous gas emboli (VGE) were monitored with echocardiography. RESULTS: Decompression sickness (DCS) incidence at 3.5 psia with ARGOX at 7.3 psia (C) was significantly higher than with oxygen breathing with or without staged decompression: there was 78% DCS for C compared with 33% and 55% DCS, respectively, for A and B. The corresponding VGE incidences were 73% (C) compared with 33% (A) and 45% (B). CONCLUSION: Preoxygenation at a 7.3-psia stage resulted in a higher DCS risk at 3.5 psia than ground level preoxygenation. It is suggested that an 8.0-psia stage pressure could eliminate this difference. Unfavorable results after preoxygenation with ARGOX indicate argon on-gassing was significant.

The risk of altitude decompression sickness at 12,000 m and the effect of ascent rate.

INTRODUCTION: Loss of aircraft cabin pressurization can result in very rapid decompression rates. The literature contains reports of increased or unchanged levels of altitude decompression sickness (DCS) resulting from increasing the rate of decompression. We conducted two prospective exposure profiles to quantify the DCS risk at 12,192 m (40,000 ft), and to determine if there was a greater DCS hazard associated with a much higher rate of decompression than typically used during past DCS studies. METHODS: The 63 human subjects participated in 80 altitude chamber decompression exposures to a simulated altitude of 12,192 m (2.72 psia; 18.75 kPa) for 90 min, following preoxygenation with 100% oxygen for 90 min. Half of the subject-exposures involved an 8-min decompression (1,524 mpm; 5,000 fpm) and the other half experienced a 30-s decompression (mean of 24,384 mpm; 80,000 fpm). Throughout each ascent and exposure, subjects were seated at rest and breathed 100% oxygen. At altitude, they were monitored for precordial venous gas emboli (VGE) and DCS symptoms. RESULTS: The higher decompression rate yielded 55.0% DCS and 72.5% VGE and the lower rate produced 47.5% DCS and 65.0% VGE. Chi square and log rank tests based on the Kaplan-Meier analyses indicated no difference in the incidence or onset rate of DCS or VGE observed during the two profiles. CONCLUSION: Decompression rate to altitude up to 24,384 mpm was found not to have an effect on DCS risk at altitude. However, research is needed to define the DCS risk with decompression rates greater than 24,384 mpm. It was also found that the onset time to DCS symptoms decreases as altitude increases.

Muscle activity in pilots with and without pressure breathing during acceleration.

BACKGROUND: Fighter pilots are frequently exposed to high acceleration (+Gz) forces during sorties. To counter these forces the pilots wear anti-G ensembles, use positive pressure breathing for G protection (PBG), and perform anti-G straining maneuvers (AGSMs). The purpose of this study was to analyze the muscle activity during sustained high G when no positive pressure breathing was used (control) compared with that during the use of PBG. METHOD: Seven Swedish Air Force fighter pilots volunteered to be exposed to gradual and rapid onset runs to +9 Gz with and without PBG in a human centrifuge. Surface electromyography was recorded from the intercostals, rectus abdominis, vastus lateralis, biceps femoris, and gastrocnemius lateralis. Measured variables included mean muscle activity, relative time with high muscle activity levels, and individual activation preferences. RESULTS: G duration tolerance was significantly longer (p = 0.028) when PBG was used (57 s) compared with control (32 s) during rapid onset runs. The vastus lateralis and the gastrocnemius lateralis generated activity > 50% of a reference contraction for a longer relative time during control (5.8% and 33.6%, respectively) than during PBG (0.3% and 12.7%, respectively). Cumulative muscle activity during acceleration was compared between trials and indicated that some pilots preferred contracting their leg muscles and others their abdominal muscles. CONCLUSION: G duration tolerance time increased when PBG was used during rapid onset sustained exposures. Less relative time with high muscle activity was seen during the use of PBG in two groups of leg muscles. The pilots seemed to have individual muscle activation sequence preferences while performing the AGSMs.

Pulmonary decompression sickness at altitude: early symptoms and circulating gas emboli.

INTRODUCTION: Pulmonary altitude decompression sickness (DCS) is a rare condition. 'Chokes' which are characterized by the triad of substernal pain, cough, and dyspnea, are considered to be associated with severe accumulation of gas bubbles in the pulmonary capillaries and may rapidly develop into a life-threatening medical emergency. This study was aimed at characterizing early symptomatology and the appearance of venous gas emboli (VGE). METHODS: Symptoms of simulated-altitude DCS and VGE (with echo-imaging ultrasound) were analyzed in 468 subjects who participated in 22 high altitude hypobaric chamber research protocols from 1983 to 2001 at Brooks Air Force Base, TX. RESULTS: Of 2525 subject-exposures to simulated altitude, 1030 (41%) had symptoms of DCS. Only 29 of those included DCS-related pulmonary symptoms. Of these, only 3 subjects had all three pulmonary symptoms of chokes; 9 subjects had two of the pulmonary symptoms; and 17 subjects had only one. Of the 29 subject-exposures with pulmonary symptoms, 27 had VGE and 21 had severe VGE. The mean onset times of VGE and symptoms in the 29 subject-exposures were 42 +/- 30 min and 109 +/- 61 min, respectively. In 15 subjects, the symptoms disappeared during recompression to ground level followed by 2 h of oxygen breathing. In the remaining 14 cases, the symptoms disappeared with immediate hyperbaric oxygen treatment. CONCLUSIONS: Pulmonary altitude DCS or chokes is confirmed to be a rare condition. Our data showed that when diagnosed early, recompression to ground level pressure and/or hyperbaric oxygen treatment was 100% successful in resolving the symptoms.

The effect of simulated weightlessness on hypobaric decompression sickness.

BACKGROUND: A discrepancy exists between the incidence of ground-based decompression sickness (DCS) during simulated extravehicular activity (EVA) at hypobaric space suit pressure (20-40%) and crewmember reports during actual EVA (zero reports). This could be due to the effect of gravity during ground-based DCS studies. HYPOTHESIS: At EVA suit pressures of 29.6 kPa (4.3 psia), there is no difference in the incidence of hypobaric DCS between a control group and group exposed to simulated weightlessness (supine body position). METHODS: Male subjects were exposed to a hypobaric pressure of 29.6 kPa (4.3 psi) for up to 4 h. The control group (n = 26) pre-oxygenated for 60 min (first 10 min exercising) before hypobaric exposure and walking around in the altitude chamber. The test group (n = 39) remained supine for a 3 h prior to and during the 60-min pre-oxygenation (also including exercise) and at hypobaric pressure. DCS symptoms and venous gas emboli (VGE) at hypobaric pressure were registered. RESULTS: DCS occurred in 42% in the control and in 44% in simulated weightlessness group (n.s.). The mean time for DCS to develop was 112 min (SD +/- 61) and 123 min (+/- 67), respectively. VGE occurred in 81% of the control group subjects and in 51% of the simulated weightlessness subjects (p = 0.02), while severe VGE occurred in 58% and 33%, respectively (p = 0.08). VGE started after 113 min (+/- 43) in the control and after 76 min (+/- 64) in the simulated weightlessness group. CONCLUSIONS: No difference in incidence of DCS was shown between control and simulated weightlessness conditions. VGE occurred more frequently during the control condition with bubble-releasing arm and leg movements.

The effect of repeated altitude exposures on the incidence of decompression sickness.

INTRODUCTION: Repeated altitude exposures in a single day occur during special operations parachute training, hypobaric chamber training, unpressurized flight, and extravehicular space activity. Inconsistent and contradictory information exists regarding the risk of decompression sickness (DCS) during such hypobaric exposures. HYPOTHESIS: We hypothesized that four short exposures to altitude with and without ground intervals would result in a lower incidence of DCS than a single exposure of equal duration. METHODS: The 32 subjects were exposed to 3 different hypobaric exposures--condition A: 2 h continuous exposure (control); condition B: four 30-min exposures with descent/ascent but no ground interval between the exposures; condition C: four 30-min exposures with descent/ascent and 60 min of ground interval breathing air between exposures. All exposures were to 25,000 ft with 100% oxygen breathing. Subjects were observed for symptoms of DCS, and precordial monitoring of venous gas emboli (VGE) was accomplished with a SONOS 1000 echo-imaging system. RESULTS: DCS occurred in 19 subjects during A (mean onset 70+/-29 min), 7 subjects in B (60+/-34 min), and 2 subjects in C (40+/-18 min). There was a significant difference in DCS incidence between B and A (p = 0.0015) and C and A (p = 0.0002), but no significant difference between B and C. There were 28 cases of VGE in A (mean onset 30+/-23 min), 21 in B (41+/-35 min), and 21 in C (41+/-32 min) with a significant onset curve difference between B and A and between C and A, but not between B and C. Exposure A resulted in four cases of serious respiratory/neurological symptoms, while B had one and C had none. All symptoms resolved during recompression to ground level. CONCLUSION: Data indicate that repeated simulated altitude exposures to 25,000 ft significantly reduce DCS and VGE incidence compared with a single continuous altitude exposure.

Heat stress effects for USAF anti-G suits with and without a counter-pressure vest.

BACKGROUND: Aircrew have reported increased heat stress when wearing the USAF Combined Advanced Technology Enhanced Design G-Ensemble or COMBAT EDGE (CE). The perceived thermal burden has been attributed to the fact that CE includes an inflatable counter-pressure vest to ease the work of positive pressure breathing during G (PBG). This study compared the heat load of CE with that of the standard USAF anti-G system (STD) without the vest, and measured heat stress effects on G-tolerance in both suits. METHODS: This study had 12 subjects (6 of them aircrew) who participated. Simulated preflight thermal stress (20 min walking at 35 degrees C with 85% relative humidity and radiant heat) was followed by return to a cooler environment (21 degrees C). G-tolerance and subjective stress levels were determined on the human centrifuge before and after the heat stress. Body weight, rectal and skin temperatures, and blood parameters were also assessed. RESULTS: Baseline relaxed tolerance for +Gz gradual onset runs (GORs) were (mean +/- SD) 7.6 +/- 1.3 G for CE and 7.1 +/- 0.8 G for STD (p < 0.05). Maximal rectal temperature following heat stress peaked at 38.1 +/- 0.4 degrees C for both CE and STD, and mean nude weight loss was 1.10 +/- 0.24 kg for both. Relaxed GOR tolerances after heat stress were 7.1 +/- 1.3 for CE and 6.3 +/- 0.9 for STD (p < 0.01). The heat stress significantly reduced G tolerance for both CE and STD (p < 0.01). CONCLUSIONS: Simulated preflight activity in hot conditions revealed no significant difference between CE and STD with regard to maximal core and skin temperature elevations or dehydration levels. CE supported a significantly higher baseline relaxed G-tolerance than STD, an advantage that persisted after heat stress and dehydration.